Merck's Gerberding discusses advantages, challenges of vaccines

Eighteen months ago, Julie Gerberding left her position as CDC director to head up Merck's vaccine unit, which is responsible for making 14 of the 17 vaccines recommended for kids and nine of the 10 shots adults should received. Once an undesirable area of industry, vaccine development has enjoyed an renaissance over the last several years as drugmakers employ new technology to access lucrative markets. In a interview with Xconomy, Gerberding explores the advantages and challenges vaccines present to Big Pharma. Report

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.